Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes

Gaoqiang Xie,Xingzi Yang,Min Li,Tao Wu,Shenshen Li,Anushka Patel,Runlin Gao,Yihong Sun,Phyo Kyaw Myint,Yangfeng Wu,Xian Li

doi:10.1186/s12944-017-0544-0

Abstract

BackgroundThe evidence of adherence to statin decreasing risk of major adverse cardiovascular events (MACEs) is still lack among patients discharged with acute coronary syndrome (ACS).Our objective is to determine the relationship between six-month adherence to statins and subsequent risk of MACEs in patients discharged with ACS.MethodsUsing two prospective registry cohorts (CPACS-1 and -2), we analyzed data from 12,516 consecutive patients with ACS who were prescribed statin at hospital discharge and survived beyond 6 months without recurrent myocardial infarction (MI) or stroke. Adherence to statin was defined as good (using statin at discharge and 6 months without declined dosage) and poor adherence groups (using statin at discharge but declining dosage or stopping at 6 months). We compared the hazard ratios of all-cause mortality and MACE in subsequent 6 months between groups, using Cox-regression models, adjusting for multiple potential confounders.ResultsSeventy two percent of patients adhered to statin therapy at 6 months. The incident MACE in the poor adherence group was significantly higher than in good adherence group (2.7% vs. 1.8%, p = 0.002). Compared with poor adherence group, the good adherence group showed a 27% lower relative risk of MACE during the 6 month follow up (fully-adjusted hazard ratio (HR) = 0.73; 95%CI: 0.56–0.97). The protective effects of good adherence were similar in groups with different statin dose as well as groups by other baseline clinical characteristics and treatments (p > 0.05 for interaction).ConclusionOur study highlights the importance of adherence to statin therapy in prevention of MACE and clinicians should aim to achieve higher dosage if tolerable.Clinical trial registrationCPACS2 was registered on URL: http://www.anzctr.org.au/default.aspx and unique identifier is ACTRN12609000491268. CPACS1 was not a clinical trial and thus not registered.

Highlights

The evidence of adherence to statin decreasing risk of major adverse cardiovascular events (MACEs) is still lack among patients discharged with acute coronary syndrome (ACS)
We examined the relationship between six-month adherence to statin post ACS and MACE in the following 6 months among 12,516 ACS patients who had been prescribed to use statin at hospital discharge
Our results demonstrate that good adherence to statin in the first 6 months after discharge is associated with subsequent lower incidence of MACE in a large unselected Chinese ACS patient population

Summary

Introduction

The evidence of adherence to statin decreasing risk of major adverse cardiovascular events (MACEs) is still lack among patients discharged with acute coronary syndrome (ACS). Our objective is to determine the relationship between six-month adherence to statins and subsequent risk of MACEs in patients discharged with ACS. Despite the strong evidence of protective effect of statins on subsequent cardiovascular risk, the uptake of statin therapy in China was modest after ACS; recent studies have indicated ~80% statin prescription at discharge which is compounded by subsequent attrition to adherence rates of less than 60% by 12 months of follow-up [12, 13] Long term use of statins reduces the subsequent risk of major adverse cardiovascular events (MACE) including mortality [3,4,5,6] when used in accordance with international clinical practice guidelines including Chinese guidelines [7,8,9,10,11].

Objectives

Methods

Results

Discussion

Conclusion